AUG 2 6 2002 SE TRADEMARIA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: George Heavner, et al.

Serial No.: 09/920,137

Art Unit: 1645

Filed

: August 1, 2001

Examiner:

For

ANTI-THE ANTIBODIES,

COMPOSITIONS,

METHODS

AND

USES

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Washington, D.C. 20231 on

(myest 21, 2002

Guy Kevin Townsend (Name of applicant, assignee, or Registered Representative)

JajK (Signature)

Quyest 21 2002

pate of Signature)

RECEIVED AUG 2 8 2002

TECH CENTER 1600/2900

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

\boxtimes In accordance with §1.97(b), since this information
Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
(other than a continued prosecution application under §1.53(d)),
within three months of the date of entry into the national
stage of the above identified application as set forth in
§1.491, or before the mailing date of a first Office Action on
the merits of the above-identified application, or before the
mailing date of a first Office Action after the filing of a
request for continued examination under §1.114, no additional
fee is required.
In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with \square the
first or _second After Final Submission, therefore:
<pre>Statement in Accordance with §1.97(e)</pre>
(attached); or
Please charge Deposit Account No. 10-0750/ /
the fee of $$180.00$ as set forth in $$1.17(p)$.
☐ In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or an
action that otherwise closes prosecution and that it is
accompanied by one of:
Statement in Accordance with §1.97(e)
(attached); or

☐ Please charge Deposit Account No. 10-0750/
the fee of \$180.00 as set forth in §1.17(p)
In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).
igtiim Copies of each of the references listed on the
attached Form PTO-1449 are enclosed herewith.
Copies of references listed on the attached Form PTO 1449 are enclosed herewith EXCEPT THAT:
In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
igtimes There are no listed references which are not in the English language.
The relevance of those listed references which are not in the English language is as follows:

•

Attached are copies of search report(s) from
corresponding patent application(s), which are listed on the
attached Submission Under MPEP 609 D.
Attached are the following non-published pending
patent applications which may be deemed relevant, which are
listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/CEN-250/GKT. This form is submitted in triplicate.

Respectfully submitted,

Guy Kevin Townsend

Reg. No. 34,033

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-2517 DATED: 8.21.02



SUBMISSION UNDER MPEP 609 D

Application Number Filing Date 09/920,137 August 1, 2001 First Named Inventor Group Art Unit George Heavner 1645 Examiner Name Attorney Docket Number CEN-250


Page 1 of 1

		U.S. PA	TENT DOCUMENTS		
			U.S. Patent Document		
Examiner Initials	Cite No.1	Name of Patentee or Applicant of Cited Document	Number	Kind Code ² (if known)	Pages, Columns, Lines, where relevant passages o relevant figures appear
*					
				RF	CEIVED
				Al	G 2 8 2002
···				1 ECH (ENTER 1600/2900
		EOREIGN	PATENT DOCUMENTS		

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite	Name of Patentee or Applicant of Cited Document	Foreign Patent Document Pages, Columns, Lines, where relevant passages or relevant figures appear			T [®]	
	,,,,,						
						- 11 - 11	
	<u> </u>	OTHER PRIOR ART - NO					
Examiner 's Initials*	Cite No. ¹	Include name of the author (in Catitle of the item (book, magazine volume-issue number(s	, journal, se	erial, sympo	osium, catalog	g, etc.), date, page(s),	T²
- Indias		PCT Search Report PCT/US 01/24785	dated June 2	28, 2002			

Examiner	Date	
Signature	Considere	<u> </u>





PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a collection of information unless it displays	a valid OMB control number.
Application Number	09/920,137
Filing Date	August 1, 2001
First Named Inventor	George Heavner
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	CEN-250

U.S. PATENT DOCUMENTS U.S. Patent Document Date of Publication Pages, Columns, Lines, Name of Patentee or Applicant Kind Code² Cite where relevant passages Examiner of Cited Document of Cited Document Initials or relevant figures appear (if known) Number mm-dd-yyyy No.1 08/05/1997 Α Boyle et al. 5,654,407 12/16/1997 Α Wolpe et al. 5.698.419

FOREIGN PATENT DOCUMENTS

Initials		Foreign Patent Document		ent	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant		
	-	Cite No. ¹	Office ³	Number⁴ K	indCode ⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T⁵
			wo	91/09967	A1	Celltech Limited	07/11/1991		
		wo	96/33735	A1	Cell Genesys Inc.	10/31/1996			
		wo	97/29131	A1	BASF AG	08/14/1997			
		EP	0525570	A2	Miles Inc.	02/03/1993			
								1	


Examiner	Date
Signature	Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.





PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 2

a collection of information unless it displays	a valid OMB control number.
Application Number	09/920,137
Filing Date	August 1, 2001
First Named Inventor	George Heavner
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	CEN-250

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
VIII.		M. MENDEZ ET AL., "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice", Nature Genetics, Vol. 15, No. 2, February 1997, pages 146-156 XP002067603	
-	-	S. STEPHENS ET AL., "Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses". Immunology, Vol. 85, No. 4, August 1995, pages 668-674, XP000881488	
		S. SIEGEL ET AL., "The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo", Cytokine, Vol. 7, No. 1, January 1995, pages 15-25, XP000990566	
		E. RANKIN ET AL., "The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis", British Journal of Rheumatology, Vol. 34, No. 4, April 1995, pages 334-342, XP000674590	
		TEUEIVEU	<u>.</u>
	-	AUG 2 8 2002	
		TECH CENTER 1600/2900	
		- Ever	
- 1			

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.